Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
OPNT - Opiant Pharmaceuticals Inc
0.81(8.68%)8:49:24 PM 1/25/2021
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics


Related Peers

Stock news

    The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14) * Acceleron Pharma Inc (NASDAQ: XLRN) (announced orphan drug designation for sotatercept in pulmonary arterial hypertension) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Affimed NV (NASDAQ: AFMD) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) - announced a deal to be bought by AstraZeneca plc (NASDAQ: AZN) for $39 billion * Agios Pharmaceutic...

    Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

    SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases ...

    Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing

    SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (“Agreement”) with a syndicate of Pontifax Medison Finance (“Pontifax”), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe’s leading growth debt firm. Opiant plans to...

    Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors

    SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with over 20 years of commercial and executive experience, to Chairman of its Board of Directors, effective January 1, 2021. Mr. Collard joined the Opiant board in 2018. Gabrielle Silver, M.D., who has se...

    Where Do Hedge Funds Stand On Opiant Pharmaceuticals, Inc. (OPNT)?

    In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

    OPNT: Increased NARCAN Nasal Spray Sales Leads to Increased Royalties for Opiant…

    By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update Update on OPNT003 Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is developing OPNT003, an intranasal (IN) formulation of nalmefene (a naltrexone derivative), which the company is developing as a long-lasting opioid antagonist for the treatment of opioid overdose. In 2018, Opiant received a $7.4 million grant from the

    Opiant Pharmaceuticals: Q3 Earnings Insights

    Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results.Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the estimate of ($0.21).Revenue of $9,106,000 decreased by 55.88% from the same period last year, which beat the estimate of $7,760,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Opiant Pharmaceuticals hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov...

    Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

    SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020, and provided a corporate update. Recent highlights include: * OPNT003 nasal nalmefene for opioid overdose   -  Opiant to use Aptar Pharma’s Unit Dose System -  Upcoming FDA meeting in December to review Pharma...